Close Menu
Home › DiamiR Lands $2.8M SBIR Grant for MicroRNA Detection in Alzheimer's

DiamiR Lands $2.8M SBIR Grant for MicroRNA Detection in Alzheimer's

Mar 15, 2017
|
staff reporter

NEW YORK (GenomeWeb) – The National Institutes of Health has awarded an approximately $2.8 million Phase IIB Small Business Innovation Research (SBIR) grant to microRNA diagnostics firm DiamiR.

The three-year grant from the National Institute on Aging will help the company develop its first test, CogniMir, CEO Kira Sheinerman said in a statement. The test is targeted at early-stage Alzheimer's disease patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
25
Featured Webinar

Cell-free DNA Testing for Fetal Aneuploidy: Lessons Learned and Implications for Clinical Practice

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul
31
Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

What's Popular?

In Molecular Diagnostics

  1. Myriad Genetics Settles Improper Medicare Billing Complaint for $9.1M

  2. Cowen, William Blair, JP Morgan Initiate Coverage of Adaptive Biotechnologies

  3. HiberGene Outlines Plans for Low-Cost Point-of-Care Molecular Diagnostic System

    Premium

  4. Roche Expands Global Access Program to Include Tuberculosis, Hepatitis, HPV Tests

  5. Curetis Submits Lower Respiratory Tract Infection Test for FDA Clearance

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.